MeiraGTx Holdings plc Ordinary Shares (MGTX) Stock
Key stats
- Market cap
- $929.70M
- Price / Earnings ratio
- 11.7x
- EPS (TTM)
- $0.76
- Volume
- Loading
- 52-week high
- $15.35
- 52-week low
- $6.62
Source: third-party data provider, as of November 13, 2026
Compare with MGTX
Recent news

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MGTX

Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
MGTX

What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
MGTX

MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
MGTX
Technical indicators
- RSI 14
- 47.36
- MACD 12/26/9
- -0.39
- EMA 9 of MACD
- -0.51
- MACD histogram
- 0.12
- SMA 50
- $10.91
- Price below SMA 50
- EMA 50
- $10.54
- Price below EMA 50
- SMA 200
- $10.37
- Price below SMA 200
- EMA 200
- $10.06
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MGTX

Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
MGTX

What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
MGTX

MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
MGTX

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
MGTX

Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
MGTX

MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
MGTX

Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
MGTX

MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MGTX

Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
MGTX
About MeiraGTx Holdings plc Ordinary Shares
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Alexandria Forbes Ph.D. | CEO, President & Director | 1965 |
| Mr. Richard Brian Giroux B.A. | COO & CFO | 1974 |
| Dr. Robert K. Zeldin M.D. | Chief Medical Officer | 1963 |
| Mr. Robert J. Wollin J.D. | General Counsel & Secretary | 1976 |
| Dr. Stuart Naylor Ph.D. | Chief Scientific Officer of Ophthalmology | 1963 |
| Dr. Michel Michaelides F.A.C.S., M.D., MBBS | Head of Clinical Ophthalmology | — |
| Ms. Christine Elise Sheehy | Senior Vice President of Global Integration | 1968 |
| Mr. Tim Randall | Senior Vice President of Risk & Internal Controls | — |
| Dr. David Rubinstein Ph.D. | Senior Vice President of Business Development | — |
| Dr. Tassos Georgiadis Ph.D. | Senior Vice President of Discovery & Preclinical Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 47.36
- MACD 12/26/9
- -0.39
- EMA 9 of MACD
- -0.51
- MACD histogram
- 0.12
- SMA 50
- $10.91
- Price below SMA 50
- EMA 50
- $10.54
- Price below EMA 50
- SMA 200
- $10.37
- Price below SMA 200
- EMA 200
- $10.06
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $16.00
- Average
- $21.50
- High
- $27.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +13.6 | +1.4 | +13.2 | +37.9 | -7.9 | +16.2 | -22.5 | -11.0 | +3.9 |



